CFH rs3916968: Understanding Your Genetic Variant
The rs3916968 variant is a genetic marker located within the CFH gene cluster, which plays a critical role in regulating the body's complement system. Research suggests this variant may contribute to phenotypic variation in retinal complement activation, a process linked to eye health.
What each genotype means
Typical CFH variant profile
This genotype represents the common state for this specific location in the CFH gene. Research into this region of the CFH cluster focuses on its role in regulating complement activation, though the specific functional impact of this variant remains limited and is not considered a primary driver of disease risk.
This is the most common genotype observed in most global populations.
Typical CFH variant profile
This genotype represents a heterozygous state for this specific location in the CFH gene. Current scientific literature indicates that while the CFH gene is central to retinal complement regulation, this specific variant has limited evidence linking it to significant clinical outcomes or disease susceptibility.
This genotype is frequently observed across diverse ancestral groups.
Typical CFH variant profile
This genotype represents the alternative state for this specific location in the CFH gene. While variants within the CFH cluster are studied for their potential contribution to phenotypic variation in retinal complement activation, this specific variant is not established as a significant clinical marker for eye health.
This genotype is present at a moderate frequency in populations of European ancestry.
What is rs3916968?
The rs3916968 variant is a single-nucleotide polymorphism (SNP) situated within the CFH gene cluster on chromosome 1. In genetics, a SNP represents a variation at a single position in the DNA sequence among individuals. This specific variant is classified as intergenic or intronic, meaning it does not reside within the protein-coding sequence of the gene itself. Instead, it sits in the non-coding regions that often serve as regulatory elements. These regions are essential for controlling when and how much of a specific protein is produced. Because rs3916968 is located in this regulatory cluster, researchers study it to understand how it might influence the expression of nearby genes, particularly those involved in the immune response within the eye.
The Role of the CFH Gene
The CFH gene encodes the complement factor H protein, a vital component of the body's innate immune system. The complement system is a group of proteins that work together to clear pathogens and damaged cells. Complement factor H acts as a regulator, preventing this system from becoming overactive and damaging healthy tissues. Because the retina is a highly active tissue with specific immune requirements, the proper regulation of complement activity is crucial for maintaining long-term eye health. Mutations or variations in the CFH gene can disrupt this balance, potentially leading to increased inflammation or altered immune responses in the retinal environment. Understanding how variants like rs3916968 interact with this system is a major focus of ongoing ophthalmic research.
Research and Evidence Strength
The evidence linking rs3916968 to specific clinical outcomes is currently considered limited. While the CFH gene cluster is well-known for its strong association with age-related macular degeneration (AMD) through other variants, rs3916968 is primarily identified as a marker contributing to variation in retinal complement activation. Genome-wide association studies (GWAS) have identified many SNPs in this region, but it is important to distinguish between a marker that is statistically associated with a trait and one that is directly causative of a disease. Current research suggests that while this variant is part of the genetic landscape of the CFH region, it does not carry the same high-impact risk profile as some other well-characterized coding variants in the same gene. Further functional studies are required to fully elucidate its biological impact.
Population Frequency
Genetic variants are distributed differently across global populations, and rs3916968 is no exception. Data indicates that this variant has a minor allele frequency (MAF) of approximately 0.35 in European populations. This frequency suggests that the variant is relatively common, meaning a significant portion of the population carries at least one copy of the minor allele. Because frequency can vary significantly based on ancestral background, these statistics are most applicable to individuals of European descent. Researchers use these frequency data to help determine if a variant is a rare mutation or a common polymorphism, which informs how they interpret its potential role in health and disease across diverse groups.
Interpreting Your Genetic Information
It is important to approach genetic information with a clear understanding of what it can and cannot tell you. A variant like rs3916968 is a piece of a much larger puzzle; it does not act in isolation, and it is not a diagnostic tool for any condition. Many factors, including lifestyle, environment, and the interaction of thousands of other genes, contribute to overall health. If you have received information about this variant from a genetic test, remember that it is a statistical association rather than a medical prediction. You cannot use this information to diagnose yourself or determine your future health outcomes. If you have concerns about your vision or eye health, the most effective step is to consult with an eye care professional or a genetic counselor who can provide context based on your personal and family medical history.
How common is this variant?
The rs3916968 variant has a minor allele frequency of approximately 0.35 in European populations, making it a common genetic polymorphism.
Frequently asked questions
Is rs3916968 a cause of macular degeneration?
No, rs3916968 is not considered a direct cause of macular degeneration. While it is located in the CFH gene cluster, which is associated with eye health, it is a marker of variation rather than a known causative mutation for the disease.
Should I be worried if I have the G allele?
There is no reason for concern based on this variant alone. It is a common genetic marker found in many healthy individuals and does not provide enough information to predict any specific health outcome.
Can I change my risk associated with this variant?
Genetic variants are fixed at birth and cannot be changed. However, maintaining a healthy lifestyle, including a balanced diet and regular eye exams, is the standard recommendation for supporting long-term eye health regardless of your genotype.
Where can I find more information about my CFH genes?
You can explore the NCBI Gene database or the GWAS Catalog for scientific information on the CFH gene. For personal health concerns, always speak with a qualified healthcare provider or a genetic counselor.
Sources & further reading
Educational information only, last refreshed 10/9/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs3916968?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CFH
This regulatory variant in the CFH locus is linked to complement system dysregulation and is a recognized genetic risk factor for age-related macular degeneration.
This variant in the complement factor H gene is associated with altered regulation of the alternative complement pathway and increased susceptibility to age-related macular degeneration.
Intronic single nucleotide variant in the CFH region associated with susceptibility to age-related macular degeneration (AMD).
Common variant in the CFH locus strongly associated with risk of age-related macular degeneration (AMD).
Intronic marker in CFH forming critical susceptibility haplotypes for choroidal neovascularization and macular atrophy.
Genomic marker in CFH frequently co-inherited in haplotypes modulating risk of late-stage visual loss from macular degeneration.